Charting the path from pioneering
biology to impactful therapeutics.
We are a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.
Learn More
MOMENTUM Clinical Trial for Patients with Myelofibrosis
The MOMENTUM Clinical Trial is a randomized, double-blind, Phase 3 trial to evaluate the activity of momelotinib versus danazol in symptomatic, anemic subjects with myelofibrosis (MF). The target enrollment for this clinical trial is 180 patients globally.